Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1787811 | 0.99 | MAPK1 (0.57) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL409305 | 0.93 | MAPK1 (0.55) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL463415 | 0.89 | MAPK1 (0.74) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL18271231 | 0.82 | PTPN7 (0.56) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL10144490 | 0.82 | HTR4 (0.61) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL13880649 | 0.79 | MAPK1 (0.58) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL4415420 | 0.79 | MAPK1 (0.55) | MAPK1OPRK1HTR4HPGDSSMYD3 | |
| SCHEMBL12514758 | 0.78 | HTR4 (0.70) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL15761009 | 0.78 | EZH2 (0.50) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL4590657 | 0.78 | MEN1 (0.62) | MAPK1OPRK1HTR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319841-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | MSD K.K. (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | MCHR1, MC5R, MCHR2 | MAPK1 1372/4885OPRK1 142/4885HTR4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.